List of Excipients in Branded Drug MEFENAMIC ACID

« Back to Dashboard

Generic Drugs Containing MEFENAMIC ACID

Company	Ingredient	NDC	Excipient
Misemer Pharmaceuticals Inc	mefenamic acid	0276-0509	D&C YELLOW NO. 10
Misemer Pharmaceuticals Inc	mefenamic acid	0276-0509	DIMETHICONE
Misemer Pharmaceuticals Inc	mefenamic acid	0276-0509	FD&C BLUE NO. 1

What are the Most Frequently-Used Excipients in MEFENAMIC ACID?

# Of NDCs	Excipient
7	D&C YELLOW NO. 10
2	DIMETHICONE
5	FD&C BLUE NO. 1

Mefenamic Acid Excipient Strategy and Commercial Opportunities

Last updated: October 3, 2026

Mefenamic acid is an established fenamate NSAID with low-cost generic competition, limited active pharmaceutical ingredient differentiation, and a formulation profile driven by poor aqueous solubility, gastrointestinal tolerability, and short recommended treatment duration. The strongest commercial opportunities are improved dissolution, lower-dose delivery, pediatric or geriatric usability, fixed-dose combinations, and region-specific formulations rather than new-molecule exclusivity.

What is the current FDA status of mefenamic acid?

Mefenamic acid is an FDA-approved oral NSAID marketed historically as Ponstel and now primarily through generic products. The reference product is mefenamic acid capsules, commonly supplied at 250 mg. The labeled adult regimen is 500 mg initially followed by 250 mg every six hours, with treatment generally limited to seven days for acute pain and three days for primary dysmenorrhea [1].

Regulatory attribute	Current position
Active ingredient	Mefenamic acid
Drug class	Fenamate NSAID
Primary dosage form	Immediate-release oral capsule
Common strength	250 mg
Reference product	Ponstel
U.S. regulatory pathway	ANDA generic competition
FDA indication	Mild-to-moderate acute pain and primary dysmenorrhea
Pediatric labeling	Patients 14 years and older in the U.S. label
Recommended treatment duration	Short term
Biologic or biosimilar exposure	None
Core composition patent risk	Low for the original molecule and conventional capsule

FDA labeling identifies class risks that affect formulation and commercialization, including gastrointestinal bleeding, cardiovascular thrombotic events, renal toxicity, hepatotoxicity, and pregnancy-related restrictions [1]. An excipient strategy cannot remove the pharmacologic risks of systemic NSAID exposure.

What patents protect mefenamic acid products?

The original compound, conventional oral dosage forms, and standard use claims are outside their practical U.S. exclusivity period. Commercial products are generally protected by regulatory compliance, manufacturing know-how, trademarks, supply reliability, and market access rather than by a live foundational patent.

A product-specific patent review should separate four claim categories:

Claim category	Commercial relevance for mefenamic acid
Compound patents	Foundational claims are expired
Conventional capsule or tablet claims	Generally weak unless tied to a specific novel formulation
Method-of-use claims	Potentially relevant for a new indication, dosing schedule, or patient population
Formulation and process claims	Main remaining route to exclusivity

Potentially defensible claims could cover:

• A supersaturating amorphous solid dispersion.
• A nanocrystal or nanosuspension with defined particle-size limits.
• A gastroprotective or enteric-release system.
• A pediatric liquid with improved chemical and physical stability.
• A low-dose product achieving bioequivalence through enhanced exposure.
• A fixed-dose combination with a non-NSAID analgesic or antispasmodic.
• A manufacturing process that produces a defined polymorph, particle morphology, or dissolution profile.

Patent value would depend on claim scope, freedom to operate, enablement, written description, obviousness risk, and whether a competitor could achieve the same dissolution target through a different excipient system. A formulation patent covering only routine surfactant selection or conventional wet granulation would face a high invalidity and design-around risk.

When does mefenamic acid lose exclusivity?

Mefenamic acid has already lost primary U.S. market exclusivity. The original product is an established generic product, and new entrants do not need to wait for a pending small-molecule exclusivity period.

Exclusivity type	Position
New chemical entity exclusivity	Expired
Original compound patent protection	Expired or commercially irrelevant
U.S. orphan exclusivity	Not applicable to the established product
Biosimilar exclusivity	Not applicable
Generic entry barrier	Bioequivalence, CMC, supply, and commercial execution
New formulation exclusivity	Possible only through a qualifying reformulation and patent or regulatory pathway

A new formulation could pursue a 505(b)(2) application if it relies partly on FDA findings for an approved mefenamic acid product while introducing a clinically or technically differentiated dosage form. The commercial value of this pathway would depend on the extent of reliance, the clinical bridge, patent listing strategy, and the resulting market exclusivity.

What excipient problems must a mefenamic acid formulation solve?

Mefenamic acid is a weakly acidic, poorly water-soluble drug. Its solubility varies with pH, and dissolution can become the rate-limiting step for absorption. The drug is also associated with gastrointestinal adverse effects typical of systemic NSAIDs. These factors make excipient selection a central product-development issue rather than a routine manufacturing decision.

The main formulation risks are:

1. Slow or variable dissolution in the gastrointestinal tract.
2. Poor wetting of hydrophobic drug particles.
3. Particle-size growth or agglomeration during storage.
4. Physical instability in amorphous systems.
5. Precipitation after intestinal dilution or pH change.
6. Capsule fill-weight and content-uniformity challenges at low dose.
7. Local gastrointestinal exposure from undissolved drug.
8. Excipient incompatibility with acidic or weakly basic microenvironments.

Mefenamic acid’s dose is high enough to make highly potent solubilizers commercially unattractive if they materially increase tablet or capsule size. The formulation should therefore improve dissolution without requiring excessive surfactant, polymer, or lipid loading.

Which excipients are most suitable for mefenamic acid?

Wetting and dissolution enhancers

Polysorbates, sodium lauryl sulfate, poloxamers, and low levels of other surfactants can improve wetting. Their use must be controlled because high concentrations may cause gastrointestinal irritation, capsule-shell interaction, or changes in dissolution after storage.

Sodium lauryl sulfate is effective as a wetting agent but requires careful level selection because it can produce an overly rapid initial release or affect tolerability. Poloxamer 188 and poloxamer 407 can improve wetting and aid solid dispersion processing, although the higher molecular-weight grade may increase viscosity and slow manufacturing.

Polymeric solid-dispersion systems

Hydroxypropyl methylcellulose, hydroxypropyl cellulose, polyvinylpyrrolidone, and copovidone can stabilize a supersaturated drug state. Soluplus and related amphiphilic polymers may improve apparent solubility through micellar or polymeric solubilization.

The primary risks are recrystallization, moisture sensitivity, high melt-processing temperature, and poor scale-up. A polymer system should be selected only after assessing:

• Drug loading.
• Glass-transition behavior.
• Hygroscopicity.
• Recrystallization during accelerated storage.
• Dissolution after dilution into biorelevant media.
• Residual solvent or thermal degradation.

A solid dispersion is commercially attractive if it produces a meaningful dissolution gain at a practical drug-to-polymer ratio. A small dissolution improvement without pharmacokinetic or manufacturing benefit is unlikely to justify new product development.

Lipid and self-emulsifying systems

Medium-chain triglycerides, mono- and diglycerides, polysorbates, and hydrophilic co-solvents can be used in self-emulsifying or lipid-based systems. These systems may increase apparent solubilization and reduce sensitivity to gastric pH.

The drawbacks are capsule compatibility, leakage risk, oxidation, fill-volume requirements, and precipitation after dispersion in intestinal fluid. A lipid formulation is most attractive when pharmacokinetic variability is significant and the formulation can demonstrate a measurable exposure advantage.

Cyclodextrins

Hydroxypropyl-beta-cyclodextrin and sulfobutyl ether-beta-cyclodextrin can increase aqueous solubility through inclusion complexation. Cost, dose burden, regulatory precedent, and the amount of cyclodextrin needed for a 250 mg dose limit the commercial attractiveness of this approach for a low-cost NSAID.

Cyclodextrins are more compelling for liquid, injectable, buccal, or pediatric products than for a standard adult capsule.

pH modifiers and buffers

Alkalinizing agents can increase mefenamic acid solubility by ionization. Suitable candidates may include sodium citrate, potassium citrate, sodium bicarbonate, or other pharmaceutically acceptable buffers. The strategy requires tight control of microenvironmental pH because excessive alkalinity can affect capsule stability, taste, gastric tolerability, and precipitation after gastric dilution.

Superdisintegrants and compression aids

For an immediate-release tablet, crospovidone, croscarmellose sodium, and sodium starch glycolate can accelerate liquid penetration and tablet breakup. Microcrystalline cellulose, mannitol, lactose, and dibasic calcium phosphate can support compression and flow.

The choice depends on the formulation objective. Crospovidone is useful where rapid wicking and low gelling are needed. Croscarmellose sodium can provide strong swelling but may increase sensitivity to compression force. Dibasic calcium phosphate improves flow and tablet robustness but may contribute to a slower dissolution profile if the formulation is poorly wetted.

What formulation technologies offer the strongest commercial opportunity?

Amorphous solid dispersion

This is the leading technical route for improving dissolution. The product can be supplied as a capsule, tablet, or sachet. Commercial value is highest where the formulation demonstrates:

• Faster dissolution across physiological pH conditions.
• Reduced fed-versus-fasted variability.
• Lower dose with equivalent exposure.
• Improved exposure consistency.
• Acceptable stability at high humidity.

The principal patent risk is obviousness. A broad claim to mefenamic acid with a conventional polymer may be difficult to defend. Stronger claims would link composition, drug loading, process conditions, solid-state properties, and dissolution performance.

Nanocrystal or nanosuspension technology

Particle-size reduction can increase surface area and dissolution rate without the high excipient burden of a solid dispersion. Stabilizers may include polymers and surfactants such as hydroxypropyl cellulose, poloxamers, or polysorbates.

Nanocrystals can support an orally disintegrating tablet, capsule, suspension, or sachet. The main development risks are aggregation, Ostwald ripening, milling contamination, and scale-up reproducibility. A defined particle-size distribution and manufacturing process may create a more defensible IP position than a simple surfactant blend.

Oral suspension

A stable suspension could address pediatric, geriatric, and dysphagia markets. The current U.S. labeling limitation for younger patients means a pediatric product would require appropriate regulatory support rather than a simple change in dosage form.

A suspension would need:

• Controlled sedimentation.
• Easy redispersion.
• Taste masking.
• Microbial protection.
• Chemical stability.
• Accurate dosing through an oral syringe.
• Packaging that limits light, oxygen, and moisture exposure.

Taste masking is difficult because mefenamic acid is poorly soluble but can produce an unpleasant mouthfeel when suspended with surfactants or fine particles. Ion-exchange resins, polymer coating, lipid coating, or multiparticulate encapsulation could be considered.

Gastroretentive or modified-release products

Modified release is technically possible but commercially constrained by the short-term indications and the need for rapid analgesic onset. A sustained-release product would need to show a meaningful benefit in dosing convenience or tolerability without delaying pain relief.

A gastroretentive product may have limited value because gastric emptying is variable and NSAID exposure remains systemic. A delayed-release or enteric product could reduce direct gastric exposure but would not eliminate systemic gastrointestinal or cardiovascular risk. Regulatory claims must avoid implying protection from NSAID class toxicity without clinical evidence.

Topical or transmucosal delivery

Topical mefenamic acid could reduce systemic exposure for localized pain, but the product would compete with established topical NSAIDs such as diclofenac, ketoprofen, and ibuprofen. Skin penetration, irritation, dose loading, and clinical differentiation are substantial barriers.

Buccal, sublingual, or oral-transmucosal delivery could provide rapid onset but would require taste masking and a low effective dose per unit. Mefenamic acid’s dose requirement makes this route less attractive than conventional oral administration.

What commercial opportunities exist for mefenamic acid?

Opportunity	Market rationale	Development difficulty	Commercial potential
Low-cost generic capsule	Established demand and simple manufacturing	Low	Moderate
Faster-dissolving capsule or tablet	May improve onset and reduce variability	Moderate	Moderate
Amorphous solid dispersion	Strongest oral enhancement route	High	Moderate to high
Nanocrystal product	Potential exposure and dissolution advantage	High	Moderate
Pediatric suspension	Addresses swallowing and dosing needs	Moderate to high	Moderate
Orally disintegrating tablet	Convenience for dysmenorrhea and acute pain	Moderate	Moderate
Fixed-dose analgesic combination	Consumer convenience and differentiation	Moderate	Moderate
Dysmenorrhea-focused product	Concentrated indication and marketing	Moderate	Moderate
Topical formulation	Lower systemic exposure proposition	High	Low to moderate
Modified-release product	Dosing convenience	High	Low to moderate

The most credible commercial segment is a differentiated oral product for dysmenorrhea, where treatment is episodic and patients may value rapid onset, small dosage form, and convenient administration. A product positioned around reduced dosing frequency is less compelling if the pharmacology and approved duration do not support prolonged exposure.

How does mefenamic acid compare with competing NSAIDs?

Mefenamic acid competes against low-cost ibuprofen, naproxen, diclofenac, ketoprofen, and prescription-strength analgesics. It lacks the broad over-the-counter infrastructure of ibuprofen and naproxen and does not have diclofenac’s extensive topical portfolio.

Attribute	Mefenamic acid	Ibuprofen	Naproxen	Diclofenac
Commercial age	Mature generic	Mature generic and OTC	Mature generic and OTC	Mature generic and OTC
Typical differentiation	Dysmenorrhea and fenamate identity	Broad OTC use	Longer duration	Broad oral and topical formats
Solubility challenge	Significant	Formulation dependent	Significant	Significant
Short-term use emphasis	Strong	Variable	Variable	Variable
Reformulation opportunity	Moderate	High but crowded	Moderate	High but crowded
Topical competition	Limited	Established	Limited	Strong
Price pressure	High	Very high	Very high	High

A mefenamic acid reformulation must offer a clear benefit over inexpensive alternatives. Faster onset, lower pill burden, pediatric usability, and a targeted dysmenorrhea product are more credible differentiators than a generic claim of improved tolerability.

What generic entry risks exist?

Generic entry risk is already realized for conventional mefenamic acid products. A new branded formulation would face:

• ANDA competition against any conventional product.
• Paragraph IV challenges against listed formulation patents.
• Design-around risk if claims rely on generic excipient classes.
• Price erosion from established manufacturers.
• Limited prescriber switching incentives.
• Difficulty demonstrating clinical superiority for a mature analgesic.
• Reimbursement pressure in markets where NSAIDs are commoditized.

Paragraph IV exposure would be relevant only for newly listed patents covering a specific reformulated product. A formulation owner should expect generic challengers to attack particle-size, polymer, dissolution, and bioequivalence claims separately. Narrow claims tied to a single excipient ratio may provide limited market protection.

What manufacturing and IP barriers matter most?

The highest-value manufacturing know-how would include:

• Controlling particle-size distribution.
• Preventing agglomeration during blending.
• Producing consistent amorphous content.
• Managing residual moisture.
• Controlling granule porosity and tablet disintegration.
• Achieving content uniformity at scale.
• Maintaining dissolution after accelerated aging.
• Preventing precipitation in biorelevant media.

Geographic protection should be evaluated separately. U.S., European, Japanese, Indian, and other national rights may have different statuses for formulation and process patents. Manufacturing in India and China can reduce cost but may increase supply-chain, technical-transfer, and enforcement considerations. A patent estate covering only the finished dosage form may not prevent API or intermediate manufacture outside the protected market.

What regulatory strategy is most practical?

A conventional generic capsule is most efficiently pursued through an ANDA with bioequivalence and CMC support. A materially different dosage form, delivery system, or indication may require a 505(b)(2) application in the U.S. The regulatory package would depend on the extent of reliance on existing mefenamic acid findings and the clinical relevance of the modification [2].

Key regulatory questions include:

• Whether the formulation changes systemic exposure.
• Whether a food-effect study is required.
• Whether comparative dissolution is sufficient.
• Whether a new clinical endpoint is needed.
• Whether the formulation changes the approved patient population.
• Whether the product remains suitable for short-term use.
• Whether excipients have adequate route-specific precedent.
• Whether the product qualifies for an Orange Book patent listing.

The FDA Inactive Ingredient Database can support excipient precedent analysis, but inclusion in the database does not establish suitability at every dose, route, or formulation type [3].

What is the overall patent strength of a mefenamic acid reformulation?

The patent estate is weak for the active ingredient and conventional dosage form but can become moderate for a technically difficult delivery system. The strongest patent position would combine composition, process, solid-state, and performance claims.

Patent strategy	Relative strength
Mefenamic acid compound claim	Very low
Conventional capsule with routine excipients	Very low
Broad surfactant-based solubilization	Low
Defined amorphous dispersion with performance limits	Moderate
Nanocrystal with particle-size and stabilizer controls	Moderate
Stable pediatric suspension with taste-masking architecture	Moderate
Novel fixed-dose combination	Moderate, subject to clinical value
Manufacturing process with measurable product attributes	Moderate
New indication alone	Variable and clinically dependent

A reformulation program should avoid relying on a single composition patent. Layered protection is preferable: formulation claims, process claims, solid-state claims, device or packaging claims, and method-of-use claims where supportable.

Key Takeaways

• Mefenamic acid is a mature generic NSAID with no meaningful foundational U.S. exclusivity.
• Poor aqueous solubility and dissolution variability are the main formulation opportunities.
• Amorphous solid dispersions and nanocrystals offer the strongest oral enhancement potential.
• Pediatric suspension and orally disintegrating products address practical administration problems.
• Dysmenorrhea-focused positioning is more commercially credible than an undifferentiated analgesic claim.
• A new product would likely require an ANDA for a conventional generic or a 505(b)(2) strategy for a differentiated dosage form.
• Formulation patents can create value, but broad excipient claims face obviousness and design-around risks.
• The main commercial barriers are price erosion, generic competition, limited treatment duration, and the absence of a strong clinical differentiation narrative.
• Systemic NSAID safety risks remain regardless of excipient selection.

FAQs

Can mefenamic acid be formulated as an oral suspension?

Yes. The main technical requirements are physical stability, redispersibility, dose uniformity, taste masking, microbial control, and chemical stability. Pediatric labeling would require regulatory support beyond simply changing the dosage form.

Which excipient is best for improving mefenamic acid dissolution?

No single excipient is universally optimal. A combination of wetting agent, polymeric precipitation inhibitor, and disintegrant is often more practical than relying on one solubilizer. The final choice should be based on dissolution, stability, tolerability, and scale-up data.

Is an amorphous solid dispersion of mefenamic acid patentable?

Potentially. Patent strength depends on the polymer system, drug loading, process, solid-state properties, stability, and demonstrated performance. A routine drug-polymer combination without unexpected results would face higher validity risk.

Does a mefenamic acid formulation patent block generic capsules?

Only if the patent claims are valid, enforceable, and cover the generic product or its approved use. A narrow reformulation patent generally does not block an unclaimed conventional capsule.

Would a topical mefenamic acid product have strong commercial potential?

The opportunity is limited because topical diclofenac and other topical NSAIDs are established competitors. A topical product would need a clear advantage in penetration, tolerability, dosing convenience, or clinical use.

References

1. U.S. Food and Drug Administration. (2023). Mefenamic acid capsules: Prescribing information. FDA-approved labeling.

2. U.S. Food and Drug Administration. (2024). Applications covered by section 505(b)(2). FDA.

3. U.S. Food and Drug Administration. (2024). Inactive Ingredient Database. FDA.

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. FDA.

5. U.S. Pharmacopeia. (2024). United States Pharmacopeia and National Formulary. U.S. Pharmacopeial Convention.